Role of imaging biomarkers in mutation-driven non-small cell lung cancer

Table 4 Summary of reported imaging biomarkers in select molecular genotypes in non-small cell lung cancer¹

Imaging feature	EGFR mutation	ALK rearrangement	ROS1 rearrangement	METex14 skipping mutation
Primary tumor	Increased ground-glass components	Purely solid lesion	Purely solid lesion	Multifocal primary lung cancers
	Presence of air bronchograms (pneumonic appearance)
		Peripheral predilection	Peripheral predilection	Peripheral predilection
Metastatic patterns	Diffuse lung metastases	Lymphangitic carcinomatosis	Lymphangitic carcinomatosis	Oligometastatic disease
		Pleural and pericardial metastasis	Pleural metastases
		Intrathoracic and distant lymphadenopathy	Intrathoracic and distant lymphadenopathy
	Lytic bone metastases	Sclerotic bone metastases	Sclerotic bone metastases	Lytic bone metastases
	High rates of brain metastases	High rates of brain metastases	High rates of brain metastases, but lower compared to EGFR and ALK	High rates of brain metastases, but lower compared to EGFR and ALK

¹Data collected from several sources[54,63,65,66,71]. EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase.